<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02582658</url>
  </required_header>
  <id_info>
    <org_study_id>P15-695</org_study_id>
    <nct_id>NCT02582658</nct_id>
  </id_info>
  <brief_title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)</brief_title>
  <acronym>REAL</acronym>
  <official_title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Austria (REAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study seeks to provide evidence of the effectiveness and obtain patient reported outcome
      (PRO) and work productivity data of the interferon-free ABBVIE REGIMEN +/- Ribavirin (RBV) in
      chronic hepatitis C virus infected participants in Austria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 6, 2015</start_date>
  <completion_date type="Actual">January 23, 2017</completion_date>
  <primary_completion_date type="Actual">January 23, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants achieving sustained virological response 12 Weeks Post-treatment (SVR12)</measure>
    <time_frame>12 Weeks after the last dose of study drug</time_frame>
    <description>Sustained virologic response is defined as hepatitis C virus ribonucleic acid (HCV RNA) levels less than 50 IU/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Usage pattern of treatment regimen in Austria</measure>
    <time_frame>Up to post treatment 12 week</time_frame>
    <description>Evaluate the usage pattern of treatment regimen type (± Dasabuvir, ± RBV, intended and actual combination, dose and duration) which is initiated at Day 0 in the Austrian population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the direct-acting antiviral (DAA) dose taken in relation to the target dose of DAA</measure>
    <time_frame>Up to post treatment week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Ribavirin (RBV) dose taken in relation to the target dose of RBV</measure>
    <time_frame>Up to post treatment week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of missed Ribavirin (RBV) treatment days in relation to the target number of RBV treatment days</measure>
    <time_frame>Up to post treatment week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with concomitant medications</measure>
    <time_frame>Day 0 to end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with co-morbidities</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in participants workability measured with the Work Productivity and Activity Impairment (WPAI):Hepatitis C questionnaire</measure>
    <time_frame>Day 0 to post treatment week 12</time_frame>
    <description>Questionnaire measures work time missed, work and non-work activity impairment due to a specified healthy problem during the past seven days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in participants quality of life measured with the EuroQol 5 dimension 5 level (EQ-5D-5L) questionnaire</measure>
    <time_frame>Day 0 to post treatment week 12</time_frame>
    <description>Five items in the EQ-5D-5L questionnaire (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) are rated on 5 levels of severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of participant activation with the Patient activation Measure (PAM-13) questionnaire.</measure>
    <time_frame>Day 0 to post treatment week 12</time_frame>
    <description>Questionnaire measures patient knowledge, skill and confidence for self-management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient support program (PSP) utilization and satisfaction assessment</measure>
    <time_frame>Up to post treatment week 12</time_frame>
    <description>Questionnaire to evaluate the frequency of use and satisfaction with the patient support program</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">172</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Chronic infection of HCV GT1 or GT4</arm_group_label>
    <description>Participants with confirmed chronic hepatitis C genotype 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN ± Ribavirin (RBV) according to standard of care and in line with the current local label</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic infection of HCV Genotype 1 (GT1) or Genotype 4 (GT4)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Treatment-naïve or -experienced adult male or female patients with confirmed chronic
        hepatitis C, genotype 1 or 4, receiving combination therapy with the interferon-free ABBVIE
        REGIMEN ± Ribavirin (RBV) according to standard of care and in line with the current local
        label

        If RBV is co-administered with the ABBVIE REGIMEN, it has been prescribed in line with the
        current local label (with special attention to contraception requirements and
        contraindication during pregnancy)

        Patients must voluntarily sign and date a patient authorization to use and disclose his/her
        anonymized health data prior to inclusion into the study

        Patient must not be participating or intending to participate in a concurrent
        interventional therapeutic trial

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander P Dorr, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LKH Hoergas-Enzenbach /ID# 145947</name>
      <address>
        <city>Gratwein-Strassengel</city>
        <zip>8112</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Universitaetsklinikum Graz /ID# 145948</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Teaching Hospital /ID# 145939</name>
      <address>
        <city>Hall</city>
        <zip>6060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Innsbruck /ID# 145938</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Linz /ID# 145942</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen Linz GmbH /ID# 145941</name>
      <address>
        <city>Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenanstalt Rudolfstiftung /ID# 145945</name>
      <address>
        <city>Vienna</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna /ID# 145943</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMZ-Sud-Kaiser-Franz-Josef-Spital der Stadt Wien /ID# 145946</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital der stadt Wien /ID# 145944</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2015</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paritaprevir</keyword>
  <keyword>Dasabuvir</keyword>
  <keyword>Ombitasvir</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>HCV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 8, 2018</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>January 11, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

